Accelerating Diagnosis of Asymptomatic Malaria

The Global Good Fund and GE have signed a licensing agreement with the diagnostics technology company Access Bio to manufacture and distribute innovative diagnostic technologies for asymptomatic malaria. The agreement covers rapid diagnostic tests, along with serology tests that assess past exposure of a population to malaria. These technologies for malaria detection were co-developed by a team of scientists and engineers at GE’s Global Research Center and Global Good. GE Ventures, a GE entity dedicated to accelerating innovation and growth with partners, drove the commercialization model for the technology and the licensing agreement between GE, Global Good and Access Bio. The collaboration is expected to help global health workers to more rapidly identify asymptomatic malaria in low-resource regions around the world. Identifying these low-level infections is considered critical to directing efforts towards malaria elimination. Global Good is an initiative of Intellectual Ventures and Bill Gates.